| Name | Title | Contact Details |
|---|
Tropiclean Pet Products, a division of Cosmos Corporation, has been providing pet owners and professionals with innovative solutions in the pet care category for over 20 years.
Inspiring SuperHumans All Over The World to Achieve Their Dream Physique and Dream Lifestyle.
For nearly three decades we have been a world leader in the production of bulk Heparin and Pancreatin for the pharmaceutical industry. We have been instrumental in the manufacture and development of pharmaceutical ingredients that have made an enormous
Partners Pharmacy is a long-term care pharmacy company in the United States. We offer a full range of services and resources to effectively serve the comprehensive medication needs of residents of skilled nursing facilities, assisted living communities, and alternative care facilities. Our unique AP PassPort™ has dramatically improved medication availability for residents, reduced medication management time for nursing, and improved compliance. Partners Pharmacy currently services over 40,000 beds with services areas in Connecticut, Florida, Maryland, Massachusetts, New Jersey, New York, Pennsylvania, Texas, and Virginia. Each location offers unparalleled, personalized service through the combined resources of our local teams and our expanding regional resources. Together we partner with the facilities we service to improve outcomes and reduce costs.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.